Kat Lange 

Kat Lange joined Avidity Biosciences in December 2024 and serves as Senior Vice President and Chief Business Officer. Ms. Lange has spent over 15 years in the life sciences and biotechnology industry, with demonstrated leadership and experience in fundraising, strategic advisory, business development and investor relations to help advance novel therapies for the treatment of neuromuscular diseases. Prior to joining Avidity, Ms. Lange served as Chief Financial Officer at Locanabio, leading the finance, investor relations and operations functions. Before Locanabio, she was an executive director in the healthcare investment banking group at J.P. Morgan where she executed more than $18 billion in equity and equity-linked financings and more than $27 billion in various business transactions. She earned a master’s degree in management science from the Judge Business School at Cambridge University and a master’s and bachelor’s degree in natural sciences also from Cambridge University. 

Charles Calderaro III

Charles Calderaro III, Chief Technical Officer, joined Avidity Biosciences in January 2025. He has more than 35 years of experience in biotechnology, pharmaceutical, and cell and gene therapy company operations and in CMC drug development. Prior to joining Avidity, Mr. Calderaro served as Chief Technical Officer for Shoreline Biosciences, where he was responsible for advancing programs in oncology and autoimmune diseases and developing scalable bioprocesses for manufacturing gene editing and cell therapies. Prior to Shoreline, he served as Global Head of Technical Operations at Kite Pharma, a Gilead Company, and Senior Vice President, Global Manufacturing at BioMarin. In addition, he previously held roles of increasing responsibility during his 14-year tenure at Genentech, a member of the Roche Group, and at Aventis Behring LLC (now CSL Behring). Mr. Calderaro was also previously a commissioned officer in the U.S. Navy. He earned his M.B.A. from Texas Christian University, his M.S. in Nuclear Engineering from the U.S. Naval Nuclear Power School, and his B.S. in Electrical Engineering from the University of Notre Dame. 

Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development

Journal of Medicinal Chemistry
Michael Cochran, Isaac Marks, Tyler Albin, Danny Arias, Philip Kovach, Beatrice Darimont, Hanhua Huang, Usue Etxaniz, Hae Won Kwon, Yunyu Shi, Matthew Diaz, Olecya Tyaglo, Arthur Levin, and Venkata Ramana Doppalapudi. Journal of Medicinal Chemistry 2024 67 (17), 14868-14884. DOI: 10.1021/acs.jmedchem.4c00803

Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development

Journal of Medicinal Chemistry
Michael Cochran, Danny Arias, Rob Burke, David Chu, Gulin Erdogan, Michael Hood, Philip Kovach, Hae Won Kwon, Yanling Chen, Michael Moon, Christopher D. Miller, Hanhua Huang, Arthur Levin, and Venkata Ramana Doppalapudi. Journal of Medicinal Chemistry 2024 67 (17), 14852-14867. DOI: 10.1021/acs.jmedchem.4c00802

2024 MDA Clinical and Scientific Conference

Initial results of the Phase 2 Open-Label Extension Study of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA-OLE™

AOC 1001-mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1

AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44 Phase 1/2 Healthy Volunteer Data

Targeting DUX4 for Silencing with AOC for the Treatment of FSHD

Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement